{
  "run_id": "eb73f6fd-37de-430a-93c6-2484c2376141",
  "prompt_variant_id": "e63c1ef1-c646-4205-ac3f-d0b67fd4b3d4",
  "api_config_name": "model_gpt_4o",
  "test_case_id": "breast_cancer_her2_positive",
  "start_time": "2025-09-01T14:03:22.454098",
  "end_time": "2025-09-01T14:04:02.827891",
  "duration_ms": 40371.479988098145,
  "success": true,
  "error_message": "",
  "entities_extracted": 15,
  "entities_mapped": 8,
  "extraction_completeness": 0.9375,
  "mapping_accuracy": 0.6666666666666665,
  "precision": 0.8125,
  "recall": 0.8125,
  "f1_score": 0.8125,
  "compliance_score": 1.0,
  "token_usage": 3273,
  "extracted_entities": [
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.95,
      "source_context": {
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.95,
      "source_context": {
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.95,
      "source_context": {
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Measurable disease per RECIST 1.1",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.9,
      "source_context": {
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "ECOG performance status 0-1",
      "type": "demographic",
      "attributes": {
        "status": "positive",
        "value": "0-1",
        "unit": null
      },
      "confidence": 0.92,
      "source_context": {
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Adequate organ function",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.88,
      "source_context": {
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Prior treatment with Trastuzumab Deruxtecan",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null
      },
      "confidence": 0.93,
      "source_context": {
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Active brain metastases",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null
      },
      "confidence": 0.94,
      "source_context": {
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy or breastfeeding",
      "type": "exclusion",
      "attributes": {
        "status": "negative",
        "value": null,
        "unit": null
      },
      "confidence": 0.91,
      "source_context": {
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.95,
      "source_context": {
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.9,
      "source_context": {
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "trastuzumab-based therapy",
      "type": "exclusion",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.85,
      "source_context": {
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.95,
      "source_context": {
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.95,
      "source_context": {
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive",
      "type": "biomarker",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null
      },
      "confidence": 0.9,
      "source_context": {
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    }
  ],
  "mcode_mappings": [
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 0",
      "mapping_rationale": "The entity 'HER2-Positive Breast Cancer' directly maps to the Mcode element 'CancerCondition' as it specifies a type of cancer diagnosis.",
      "id": "cddadc9b-74ee-4e1e-97a2-2ad0c93092d3",
      "llm_source_text_fragment": "Entity index 0",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic Breast Cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 1",
      "mapping_rationale": "The entity 'Metastatic Breast Cancer' is a specific cancer diagnosis and maps to 'CancerCondition'.",
      "id": "fb3fe065-3ece-4cec-ab50-04fd668a4466",
      "llm_source_text_fragment": "Entity index 1",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 2",
      "mapping_rationale": "This entity combines HER2 status and metastatic breast cancer, mapping to 'CancerCondition'.",
      "id": "6eb4b527-ec75-4e12-b440-45564d19e956",
      "llm_source_text_fragment": "Entity index 2",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "ECOGPerformanceStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "ecogperformancestatus",
        "display": "ECOGPerformanceStatus"
      },
      "value": "0-1",
      "mapping_confidence": 0.92,
      "source_text_fragment": "Entity index 4",
      "mapping_rationale": "The ECOG performance status is a standard measure of patient performance and maps to 'ECOGPerformanceStatus'.",
      "id": "5e127ceb-e9fa-47f0-8dfa-dd04909fbd74",
      "llm_source_text_fragment": "Entity index 4",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 0.93,
      "source_text_fragment": "Entity index 6",
      "mapping_rationale": "Trastuzumab Deruxtecan is a medication used in cancer treatment, mapping to 'CancerRelatedMedication'.",
      "id": "622a8533-57b0-49e8-bd81-a4b2756950aa",
      "llm_source_text_fragment": "Entity index 6",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-positive",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 10",
      "mapping_rationale": "HER2-positive is a biomarker status, mapping to 'GenomicVariant'.",
      "id": "4278d7b9-d2fd-42a9-a197-0713eca7dcd4",
      "llm_source_text_fragment": "Entity index 10",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "trastuzumab",
      "mapping_confidence": 0.85,
      "source_text_fragment": "Entity index 12",
      "mapping_rationale": "Trastuzumab is a standard HER2-targeted therapy, mapping to 'CancerRelatedMedication'.",
      "id": "136c4bfa-b53e-42fd-8a2a-38de9bff3ea6",
      "llm_source_text_fragment": "Entity index 12",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "GenomicVariant",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "genomicvariant",
        "display": "GenomicVariant"
      },
      "value": "HER2-Positive",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 14",
      "mapping_rationale": "HER2-Positive is a biomarker status, mapping to 'GenomicVariant'.",
      "id": "162748af-17bd-42cd-be8f-34409ffaa7f9",
      "llm_source_text_fragment": "Entity index 14",
      "source_references": []
    }
  ],
  "validation_results": {
    "valid": true,
    "errors": [],
    "warnings": [],
    "compliance_score": 1.0
  }
}